📢  Take advantage of limited-time savings on select job packs! Learn more. ➡️

Search
Header navigation
Effortlessly Order Soma Online Verified Digital Payment USA logo

Effortlessly Order Soma Online Verified Digital Payment USA

Office

Industry

Other

Find us:

About us

CLICK HERE TO ORDER – Exclusive 20% OFF! Now

Carisoprodol (Soma) is a prescription skeletal muscle relaxant used for short-term (up to 2–3 weeks) relief of acute, painful musculoskeletal conditions. It works as a central nervous system depressant to treat spasms. Common side effects include drowsiness, dizziness, and headache. It is a controlled substance due to potential misuse.

Key Details About Soma (Carisoprodol)

  • Drug Class & Mechanism: Carisoprodol is a centrally acting skeletal muscle relaxant that operates by altering neuronal activity in the spinal cord and descending reticular formation of the brain, causing muscle relaxation. It is metabolized into meprobamate, a controlled substance with sedative properties.
    • Uses: It is used for short-term treatment of discomfort related to acute, painful musculoskeletal conditions, such as muscle spasms or injuries.
    • Dosage: The typical dosage is 250 mg to 350 mg taken three times a day and at bedtime, generally limited to a 2–3 week duration.
    • Side Effects: Common side effects include sedation, dizziness, vertigo, ataxia, and headache. Serious side effects can include addiction, dependence, and allergic reactions.
    • Risks & Warnings:
      • Misuse: Carisoprodol is a Schedule IV controlled substance because it can be addictive, especially in patients with a history of substance abuse.
      • Interactions: Combining with alcohol, opioids, benzodiazepines, or other CNS depressants can lead to fatal overdoses.
      • Withdrawal: Abrupt cessation can cause withdrawal symptoms.
    • Contraindications: Should not be used by individuals with a history of acute intermittent porphyria or allergies to meprobamate or carbamates.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...